STRATEC Biomedical AG / Key word(s): Contract
STRATEC - Significant progress with new development projects
Birkenfeld, December 5, 2013
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) announces today that it has made significant progress with major development projects, including the execution of a second major agreement for 2013, and that further projects are in advanced stages of development and negotiation.
The trend predicted in numerous studies in recent years, namely that companies in the in-vitro diagnostics (IVD) industry will increasingly outsource instrumentation solutions to specialist development and production partners, is gaining further momentum for STRATEC. Having already agreed a major project with a customer in the first quarter of 2013, STRATEC has now signed a further contract with one of the leading players in the IVD industry. For both projects, development work has already been underway for some time. They are expected to make a significant contribution to STRATEC's sales performance from 2016 onwards and are therefore partly reflected in the company's current guidance. STRATEC thus continues to expect its sales for 2014 through to 2017 to show average annual growth of 8% to 12% based on 2013 sales figures.
Furthermore, the company has also reached an important milestone in the development of a higher-throughput analyzer system. Here, achievement of the acceptance criteria for validation systems - which are necessary for clinical trials - has been confirmed by the customer. This represents an important step on the way towards serial production, which is scheduled to begin in around twelve to 18 months.
Comments Marcus Wolfinger, CEO of STRATEC Biomedical AG: 'Even though our partners have already implemented four market launches of STRATEC products in the past twelve months, the latest developments represent a further major step forward. In one case, for example, we will be producing systems in Asia for the Asian markets, thus enabling us to exploit resultant benefits for the partner as a local manufacturer. We are minimizing the associated risks by means of targeted cooperation with experienced international players on location.'
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from:
End of Corporate News
05.12.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
|Company:||STRATEC Biomedical AG|
|Phone:||+49 (0)7082 7916 0|
|Fax:||+49 (0)7082 7916 999|
|Listed:||Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart|
|End of News||DGAP News-Service|